• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.

作者信息

Pharoah Paul D P, Abraham Jean, Caldas Carlos

出版信息

J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.

DOI:10.1093/jnci/djs312
PMID:22851268
Abstract
摘要

相似文献

1
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验 以及 回复：CYP2D6和UGT2B7基因分型与他莫昔芬治疗的乳腺癌患者复发风险
J Natl Cancer Inst. 2012 Aug 22;104(16):1263-4; author reply 1266-8. doi: 10.1093/jnci/djs312. Epub 2012 Jul 31.
2
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.回复：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1265-6; author reply 1266-8. doi: 10.1093/jnci/djs305. Epub 2012 Jul 31.
3
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.关于：绝经后内分泌反应性乳腺癌患者的CYP2D6基因分型与他莫昔芬反应：国际乳腺癌研究组1-98试验
J Natl Cancer Inst. 2012 Aug 22;104(16):1264; author reply 1266-8. doi: 10.1093/jnci/djs304. Epub 2012 Jul 31.
4
CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.细胞色素P450 2D6基因分型作为绝经后女性辅助性他莫昔芬获益的标志物：经验教训
J Natl Cancer Inst. 2012 Mar 21;104(6):427-8. doi: 10.1093/jnci/djs139. Epub 2012 Mar 6.
5
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.CYP2D6 和 UGT2B7 基因型与他莫昔芬治疗的乳腺癌患者复发风险。
J Natl Cancer Inst. 2012 Mar 21;104(6):452-60. doi: 10.1093/jnci/djs126. Epub 2012 Mar 6.
6
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.CYP2D6 基因型与内分泌治疗反应性乳腺癌绝经后妇女的关系：乳腺国际研究组 1-98 试验。
J Natl Cancer Inst. 2012 Mar 21;104(6):441-51. doi: 10.1093/jnci/djs125. Epub 2012 Mar 6.
7
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.关于：细胞色素P450 2D6的药物基因组变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1331-2; author reply 132-3. doi: 10.1093/jnci/djn272. Epub 2008 Sep 9.
8
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.CYP2D6的药物基因组变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.
9
Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.关于：细胞色素P450 2D6的药物基因组学变异与绝经后乳腺癌最佳辅助内分泌治疗的选择：一项建模分析
J Natl Cancer Inst. 2008 Sep 17;100(18):1331; author reply 1332-4. doi: 10.1093/jnci/djn269. Epub 2008 Sep 9.
10
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.CYP2D6 抑制与丹麦基于人群研究中的乳腺癌复发。
J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

引用本文的文献

1
Clinical Genotyping to Personalize Adjuvant Tamoxifen Treatment in ER-Positive Breast Cancer Patients: Current Status of a Controversy.临床基因分型以实现雌激素受体阳性乳腺癌患者辅助他莫昔芬治疗的个体化：争议现状
Cancers (Basel). 2021 Feb 12;13(4):771. doi: 10.3390/cancers13040771.
2
CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.CYP2D6 表型、他莫昔芬和 WECARE 研究中对侧乳腺癌的风险。
Breast Cancer Res. 2018 Dec 10;20(1):149. doi: 10.1186/s13058-018-1083-y.
3
Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.
细胞色素 P450 遗传变异与美国印第安人和阿拉斯加原住民人群中他莫昔芬生物转化相关。
Clin Transl Sci. 2018 May;11(3):312-321. doi: 10.1111/cts.12542. Epub 2018 Feb 13.
4
Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.细胞色素P-450 2D6（CYP2D6）基因型与他莫昔芬治疗患者的乳腺癌复发：评估杂合性缺失的重要性
Am J Epidemiol. 2017 Jan 15;185(2):75-85. doi: 10.1093/aje/kww178. Epub 2016 Dec 17.
5
Breast cancer recurrence in relation to antidepressant use.乳腺癌复发与抗抑郁药使用的关系。
Cancer Causes Control. 2016 Jan;27(1):125-36. doi: 10.1007/s10552-015-0689-y. Epub 2015 Oct 30.
6
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.乳腺癌中CYP2D6基因座杂合性缺失：对种系药物遗传学研究的启示。
J Natl Cancer Inst. 2014 Dec 8;107(2):dju401. doi: 10.1093/jnci/dju401.
7
Status of adjuvant endocrine therapy for breast cancer.乳腺癌辅助内分泌治疗现状。
Breast Cancer Res. 2014;16(2):206. doi: 10.1186/bcr3636.
8
'Toxgnostics': an unmet need in cancer medicine.“毒理学诊断学”：癌症医学中的未满足需求。
Nat Rev Cancer. 2014 Jun;14(6):440-5. doi: 10.1038/nrc3729. Epub 2014 May 15.
9
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.关于：肿瘤来源DNA与种系DNA中CYP2D6基因型的一致性。
J Natl Cancer Inst. 2014 Apr 3;106(5):dju063. doi: 10.1093/jnci/dju063.
10
Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.与他莫昔芬疗效相关的代谢和转运：持续争议的新视角。
Future Oncol. 2014 Jan;10(1):107-22. doi: 10.2217/fon.13.168.